Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €62.67 EUR
Change Today +0.76 / 1.23%
Volume 92.8K
MOR On Other Exchanges
As of 3:35 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Arndt Schottelius

Chief Development Officer and Member of Management Board,Morphosys AG
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2014


Dr. Arndt Schottelius serves as the Chief Development Officer of MorphoSys UK Ltd. Dr. Schottelius has been the Chief Development Officer and a Member of Management Board at Morphosys AG since December 29, 2008. He is responsible for coordinating the Group's expanding therapeutic antibody development activities including pre-clinical and clinical drug development. He was employed at Genentech Inc., South San Francisco, where he served as a Director of Immunology, Tissue ...

Read Full Background

Corporate Headquarters*

Lena-Christ-Strasse 48
Martinsried, Bavaria 82152


Phone: 49 8989 9270
Fax: 49 89 8992 7222

Board Members Memberships*

There is no Board Members Memberships data available.


There is no Education data available.

Other Affiliations*

Annual Compensation*

Total Annual Compensation€504,543

Stock Options*

Long Term Incentive Plan€491,685
All Other Compensation€119,161

Total Compensation*

Total Annual Cash Compensation€623,704
Total Short Term Compensation€504,543
Other Long Term Compensation€119,161
Total Calculated Compensation€1,115,389
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €62.67 EUR +0.76


Daniel M. Junius Chief Executive Officer, President and Director
ImmunoGen, Inc.
John W. Varian Chief Executive Officer and Director
XOMA Corporation
Jan G. J. van de Winkel Ph.D.Co-Founder, Chief Executive Officer and President
Genmab A/S
Edwin Moses Ph.D.Chief Executive Officer, Director and Member of Research & Development Committee
Ablynx NV
Randal J. Kirk J.D.Chairman, Chief Executive Officer and President
Intrexon Corporation
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at